摘要
目的探讨茵栀黄口服液在妊娠期肝内胆汁淤积症患者中的治疗效果。方法以2013年6月至2017年1月在我院接受治疗的66例妊娠期肝内胆汁淤积症患者作为研究对象,根据患者治疗顺序将其分成观察组和对照组,各33例。对照组患者使用熊去氧胆酸进行治疗,观察组患者使用茵栀黄口服液与熊去氧胆酸联合治疗。对比两组患者的血清指标、妊娠结局、新生儿1 min Apgar评分以及术后不良反应发生情况。结果两组患者治疗后的ALT、AST及TBA水平均降低,且观察组患者的上述指标优于对照组(P<0.05)。观察组患者的分娩孕周明显晚于对照组,产后出血量明显少于对照组;观察组新生儿出生1 min Apgar评分明显高于对照组(P<0.05)。两组患者均未发生严重的不良反应。结论茵栀黄口服液能够有效缓解妊娠期肝内胆汁淤积症的临床症状,且安全性较高,值得推广。
Objective To investigate the effect of Yinzhihuang oral liquid in patients with intrahepatic cholestasis of pregnancy. Methods A total of 66 patients with intrahepatic cholestasis of pregnancy treated from June 2013 to January2017 in our hospital were divided into observation group and control group according to the order of treatment, with 33 cas-es in each group. The control group received ursodeoxycholic acid, while the observation group received combination treat-ment of Yinzhihuang oral liquid and ursodeoxycholic acid. The serum parameters, pregnancy outcome, 1 min Apgar score of neonates and postoperative adverse reactions were compared between the two groups. Results The levels of ALT, AST and TBA in both groups decreased after treatment, and the above indexes in the observation group were better than those in the control group(P<0.05). The childbirth gestational week in the observation group was significantly later than that of the con-trol group, and the postpartum hemorrhage was significantly less than that of the control group, the 1 min Apgar score of neonates was significantly higher than that in the control group(P <0.05). No serious adverse reactions occurred in both groups. Conclusion Yinzhihuang oral liquid can effectively relieve the clinical symptoms of intrahepatic cholestasis of pregnancy, with high safety, it is worthy of promotion.
出处
《临床医学研究与实践》
2018年第7期134-135,共2页
Clinical Research and Practice
关键词
茵栀黄口服液
妊娠期肝内胆汁淤积症
熊去氧胆酸
Yinzhihuang oral liquid
intrahepatic cholestasis of pregnancy
ursodeoxycholic acid
